Danish BioTech company Samplix, which develops droplet microfluidics technology for functional single-cell analysis, has announced a €25 million first close of a financing round.
The Round
Only part of the €25 million is fresh money: the financing comprises €3 million in new capital and €22 million in shareholder convertible bonds. It was led by WLanholding GmbH, a privately owned European investment firm, with participation from all major existing shareholders. The round stays open to additional investors, with a total target of €30 million.
Dr. Werner Lanthaler, founder and Managing Director of WLan, said: “We are excited to partner with Samplix at this pivotal stage of its growth. The team has built a differentiated single-cell technology platform that solves real, persistent challenges in drug discovery. We believe Samplix is well positioned to become a category leader, and we look forward to supporting the team as they scale their impact across the industry.”
Lanthaler, former CEO of Evotec, will join Samplix’s Board of Directors within the next year and work closely with management on the company’s next growth phase.
Dr. Henrik Pfundheller, CEO of Samplix, said: “This investment is a further validation of the value our Xdrop platform brings to the antibody discovery community. We are now in a strong position to further scale our platform, deepen our partnerships with biopharma and academia, and continue pushing the boundaries of what’s possible in single-cell workflows. This is an important milestone in our mission to make drug-discovery faster, simpler, and more reliable.”
The Technology
Samplix is headquartered in Birkerød and was founded in 2013 with the aim of making high-throughput cellular screening accessible without specialised instruments. Its core product is the Xdrop platform, which encloses individual living cells and assay reagents in millions of tiny double-emulsion droplets. Each droplet acts as a miniature, self-contained reaction vessel, so researchers can observe cell behaviour. The company says the droplets work with standard flow cytometry and cell-sorting equipment, allowing high-throughput analysis and sorting of functional droplets.
The platform is used by biopharma companies and academic institutions worldwide for antibody discovery, immunotherapy, cell line development and genomic editing, among other single-cell research. Samplix says it targets a persistent early-stage drug development problem: screening cells against hard-to-target proteins, such as those embedded in cell membranes.
What’s Next
Samplix will use the capital to strengthen its balance sheet and broaden commercial adoption of Xdrop, especially in antibody discovery. It also sees a growing opportunity in AI-driven drug discovery, where large volumes of functional, cell-level data are needed to train predictive models.
